Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
BRCA1/2&DNA Repair Gene Testing
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
A novel Her2-targeted antibody-conjugate showed activity in trastuzumab emtansine-pretreated patients with Her2-positive breast cancer 2019-06-04
A dose expansion phase I clinical trial data revealed the efficacy of trastuzumab deruxtecan (DS-8201a) in trastuzumab emtansine-pretreated patients with Her2-positive breast cancer
Lorlatinib showed the anti-tumor efficacy in ALK inhibitor-pretreated NSCLC patients with ALK mutation 2019-06-04
A phase II clinical trial data revealed the efficacy of lorlatinib in ALK mutation-positive NSCLC patients who have failed prior ALK inhibitor. Furthermore, the ALK mutations identified by tissue genotype can predict the potential clinical benefits of lor
Pertuzumab Plus Trastuzumab Shows Potential Treatment-Refractory HER2-Positive Metastatic Colorectal Cancer 2019-06-04
In an ongoing, phase 2a, multiple basket study (MyPathway), combination of pertuzumab and trastuzumab showed encouraging activity in patients with treatment-refractory HER2+ metastatic CRC, especially for those with KRAS wild-type tumors.
LOXO-195 Shows Good Activity In Patients Who Have Failed After Prior Anti-TRK Therapy 2019-05-02
In a phase 1 study, LOXO-195 showed promising results in multiple cancer types after failure of initial anti-TRK therapy
Maintenance Rucaparib Shows Encouraging Disease Control In Pancreatic Cancer Patients With BRCA1, BRCA2 or PALB2 Mutation 2019-05-02
Rucaparib maintenance following platinum-based chemotherapy shows encouraging disease control in BRCA1/2 or PALB2-mutant pancreatic cancer
MET Amplification Is A Potential Biomarker For NSCLC Patients Resistant To 1st And 2nd EGFR Inhibitor Treatment 2019-05-02
A phase Ib clinical trial (TATTON) data revealed the efficacy of osimertinib plus savolitinib in MET-amplified NSCLC patients after progression on EGFR inhibitor treatment.
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
